补体C_3诊断原发性肝癌的临床意义

用免疫散射比浊法检测血清补体C_3共88例,其中肝硬化合并肝癌组20例,肝硬化组28例,另设正常对照组40例。结果发现,补体C_3含量肝硬化合并肝癌组(0.972±0.329g/L)与肝硬化组(0.604±0.177g/L)之间有极显著差异(P<0.001)。血清补体C_3含量以0.99g/L为界限,则补体C_3对肝硬化合并肝癌诊断的阳性预测值、阴性预测值、准确度分别为84.6%、74.2%、77.08%,当补体C_3与AFP联合检测时则分别上升为94.4%、90.0%、91.6%,且较r—GT与AFP联合诊断肝硬化合并肝癌的价值有所提高,进一步证实血清补体C_3可以作为诊断肝硬化合并肝癌的重要标志物。

CLINICAL SIGNIFICANCE OF SERUM COMPLEMENT C_3 IN DIAGNOSIS OF PRIMARY HEPATOCELLULAR CARCINOMA

Seram complement C_3 was determined with the nephelometric method in 88 casesincluding 20 cases of hepatocellular carcinoma (HCC), 28 liver cirrhosis(LC), 20 LC complicated by HCCand 40 healthy people. There was significant difference in complement C_3 content between the LC and LCcomplicated by HCC group. On condition that the complement C_3 content of 0.99g/L was selected asdiagnostic limit,the positive prediction value,negative prediction value and accuracy were 84.6%,74.2% and 77.08%respectively in the LC complicated by HCC group. When diagnosed with combinedassay of C_3 and alpha-fetoprotein (AFP), the positive prediction value, negative prediction value andaccuracy were elevated to 94.4%, 90.0%and 91.6%in proper order, which were higher than thosewith combined assay of serum r-glutamyltransferasre (r-GT) and AFP. These data further prove thatcomplement C_3 is a important marker in diagnosing LC complicated by HCC patients.